Look back at pharma news in week to June 22

24 June 2018

By Barbara Obstoj-Cardwell, Editor

Roche’s proposed acquisition of the already partially-owned Foundations Medicine was seen as another targeted cancer drug deal for the Swiss pharma giant. On the regulatory front, there was the clinical hold from the US Food and Drug Administration of Ziopharm Oncology’s CAR-T therapy. Also FDA Commissioner Scott Gottlieb said he was withdrawing the draft guidance in biosimilar, which has raised concerns from industry. Clinical trial results news included one positive story with positive news on Sarepta Therapeutics’ Duchenne muscular dystrophy drug, named rAAVrh.74.MHCK7, sending the firm’s shares rocketing, and negative outcomes for Anika Therapeutics’ osteoporosis candidate Cingal failing in Phase III.

Roche buys out Foundation Med in $2.4 billon bet on targeted cancer treatment

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK